Clinical Trials Browser

Phase 1/2 × thymoglobulin × Other hematologic neoplasm × Clear all

Hematologic Neoplasms

NCT00822770 2020-10-14

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin

Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT00801931 2019-03-27

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Phase 1/2 Terminated

1 enrolled 8 charts

CNSClassical hematologyLymphoidOther hematologic neoplasm

Anemia, Immunologic Deficiency Syndromes, Leukemia, Lymphoma, Neuroblastoma

NCT01050764 2018-06-27

Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells

Phase 1/2 Terminated

10 enrolled 13 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00303667 2017-12-28

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

Phase 1/2 Completed

50 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00679536 2014-01-23

Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors

Phase 1/2 Unknown

30 enrolled

Other hematologic neoplasm

Graft vs Host Disease, Leukemia

NCT00887042 2012-03-26

Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML

Phase 1/2 Unknown

35 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Clinical Trials

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors

Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML